Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stromal Cells for Xerostomia After Radiation Therapy for Head and Neck Cancer
NCT05820711Phase 1Active, not recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in xerostomia, sponsored by University of Wisconsin–Madison. Primary endpoints: Recommended Phase 2 Dose at 1 month, Number of subjects with pain >5 on a 0-10 point scale at 1 month and 2 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
xerostomia
Beyond the preview
Go deeper on NCT05820711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05820711.